Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

9.14
-0.2300-2.45%
Post-market: 9.140.00000.00%16:28 EDT
Volume:1.71M
Turnover:15.58M
Market Cap:568.13M
PE:-7.32
High:9.38
Open:9.26
Low:8.88
Close:9.37
52wk High:11.45
52wk Low:4.50
Shares:62.16M
Float Shares:62.16M
Volume Ratio:0.78
T/O Rate:2.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.22
PE(LYR):-5.78

Loading ...

Sagimet Biosciences - All Clinical Trial Sites Identified and Cro Retained for Aurora Phase 3 Trial

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences Grants 260,700 Inducement Stock Options to New Hires

Reuters
·
Aug 18

Sagimet Biosciences Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 18

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 18

Sagimet Biosciences price target raised to $56 from $49 at Canaccord

TIPRANKS
·
Aug 17

Sagimet Wins FDA IND Clearance for Phase 3 Denifanstat Acne Trial

Reuters
·
Aug 13

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and Ind Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

THOMSON REUTERS
·
Aug 13

Sagimet Biosciences Inc.: Phase 3 Clinical Trial is on Track to Initiate in Second Half of 2026

THOMSON REUTERS
·
Aug 13

Sagimet Director George Kemble Disposes of 20,206 Common Shares Worth $201,160.97

Reuters
·
Aug 13

Sagimet Biosciences Price Target Raised to $56.00/Share from $49.00 by Canaccord Genuity

Dow Jones
·
Aug 13

Edward Nash Initiates Buy on Sagimet, Citing De-Risked Late-Stage Acne Program and Significant U.S. Market Opportunity

TIPRANKS
·
Aug 12

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

Inhibikase Q2 Net Loss Widens on Higher R&D, SG&A Costs

Reuters
·
Aug 12

Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says

MT Newswires Live
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Aug 12

Sagimet Highlights Q2 Results and Dermatology Focus Shift

TIPRANKS
·
Aug 11

Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate

Benzinga Earnings
·
Aug 11

Sagimet Net Loss Widens to $14 Million in Q2 FY26; R&D Expense Climbs to $11.54 Million

Reuters
·
Aug 11

Sagimet Biosciences Q2 EPS USD -0.26

THOMSON REUTERS
·
Aug 11

Press Release: Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
Aug 11